000292073 001__ 292073
000292073 005__ 20250514105538.0
000292073 0247_ $$2doi$$a10.1002/cam4.7365
000292073 0247_ $$2pmid$$apmid:39096090
000292073 0247_ $$2pmc$$apmc:PMC11297530
000292073 0247_ $$2altmetric$$aaltmetric:165960417
000292073 037__ $$aDKFZ-2024-01581
000292073 041__ $$aEnglish
000292073 082__ $$a610
000292073 1001_ $$0P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aHemminki, Kari$$b0$$eFirst author$$udkfz
000292073 245__ $$aSurvival improvements in esophageal and gastric cancers in the Nordic countries favor younger patients.
000292073 260__ $$aHoboken, NJ$$bWiley$$c2024
000292073 3367_ $$2DRIVER$$aarticle
000292073 3367_ $$2DataCite$$aOutput Types/Journal article
000292073 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1737989406_29900
000292073 3367_ $$2BibTeX$$aARTICLE
000292073 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000292073 3367_ $$00$$2EndNote$$aJournal Article
000292073 500__ $$a#EA:Z999#
000292073 520__ $$aEsophageal cancer (EC) and gastric cancer (GC) are fatal cancers with a relatively late age of onset. Age is a negative risk factor for survival in many cancers and our aim was to analyze age-specific survival in EC and GC using the recently updated NORDCAN database. NORDCAN data originate from the Danish, Finnish, Norwegian, and Swedish nationwide cancer registries covering years 1972 through 2021 inviting for comparison of 50-year survival trends between the countries. Relative 1- and 5-year survival and 5/1-year conditional survival (i.e., survival in those who were alive in Year 1 to survive additional 4 years) were analyzed. Survival in EC showed large gains for patients below age 80 years, 5-year survival in Norwegian men reaching 30% and in women over 30% but for 80-89 year old survival remained at 10%. In contrast, hardly any gain was seen among the 80-89 year patients for 1-year survival and small gains in 5 year and 5/1-year survival. Survival gaps between age-groups increased over time. For GC there was also a clear age-related negative survival gradient but the survival gaps between the age groups did not widen over time; Norwegian male and female 5-year survival for 80-89 year old was about 20%. The age-specific survival difference in GC arose in Year 1 and did not essentially increase in 5-year survival. While there were differences in survival improvements between the countries, poor survival of the 80-89 year old patients was shared by all of them. To conclude, survival has improved steadily in younger GC and EC patients in most Nordic countries. While the 80-89 year old population accounts for nearly a quarter of all patients and their poor survival depressed overall survival, which can therefore be increased further by improving diagnostics, treatment and care of elderly EC and GC patients.
000292073 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000292073 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000292073 650_7 $$2Other$$amortality
000292073 650_7 $$2Other$$arelative survival
000292073 650_7 $$2Other$$arisk factors
000292073 650_7 $$2Other$$astomach cancer
000292073 650_7 $$2Other$$atreatment
000292073 650_2 $$2MeSH$$aHumans
000292073 650_2 $$2MeSH$$aEsophageal Neoplasms: mortality
000292073 650_2 $$2MeSH$$aEsophageal Neoplasms: epidemiology
000292073 650_2 $$2MeSH$$aStomach Neoplasms: mortality
000292073 650_2 $$2MeSH$$aStomach Neoplasms: epidemiology
000292073 650_2 $$2MeSH$$aMale
000292073 650_2 $$2MeSH$$aFemale
000292073 650_2 $$2MeSH$$aAged, 80 and over
000292073 650_2 $$2MeSH$$aAged
000292073 650_2 $$2MeSH$$aMiddle Aged
000292073 650_2 $$2MeSH$$aAge Factors
000292073 650_2 $$2MeSH$$aRegistries
000292073 650_2 $$2MeSH$$aScandinavian and Nordic Countries: epidemiology
000292073 650_2 $$2MeSH$$aAdult
000292073 650_2 $$2MeSH$$aSurvival Rate
000292073 7001_ $$00000-0001-7600-7143$$aZitricky, Frantisek$$b1
000292073 7001_ $$0P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aFörsti, Asta$$b2$$udkfz
000292073 7001_ $$aHemminki, Otto$$b3
000292073 7001_ $$aLiska, Vaclav$$b4
000292073 7001_ $$00000-0001-7103-8530$$aHemminki, Akseli$$b5
000292073 773__ $$0PERI:(DE-600)2659751-2$$a10.1002/cam4.7365$$gVol. 13, no. 15, p. e7365$$n15$$pe7365$$tCancer medicine$$v13$$x2045-7634$$y2024
000292073 8564_ $$uhttps://inrepo02.dkfz.de/record/292073/files/Cancer%20Medicine%20-%202024%20-%20Hemminki%20-%20Survival%20improvements%20in%20esophageal%20and%20gastric%20cancers%20in%20the%20Nordic%20countries%20favor.pdf
000292073 8564_ $$uhttps://inrepo02.dkfz.de/record/292073/files/Cancer%20Medicine%20-%202024%20-%20Hemminki%20-%20Survival%20improvements%20in%20esophageal%20and%20gastric%20cancers%20in%20the%20Nordic%20countries%20favor.pdf?subformat=pdfa$$xpdfa
000292073 909CO $$ooai:inrepo02.dkfz.de:292073$$pVDB
000292073 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000292073 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000292073 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000292073 9141_ $$y2024
000292073 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER MED-US : 2022$$d2023-10-26
000292073 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000292073 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000292073 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000292073 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-04-16T15:13:13Z
000292073 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-04-16T15:13:13Z
000292073 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Double anonymous peer review$$d2021-04-16T15:13:13Z
000292073 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-04-16T15:13:13Z
000292073 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-26
000292073 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-26
000292073 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000292073 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-26
000292073 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-26
000292073 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000292073 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-26
000292073 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-26
000292073 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-26
000292073 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-26
000292073 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-10-26
000292073 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-10-26
000292073 9201_ $$0I:(DE-He78)Z999-20160331$$kZ999$$lErimitus im DKFZ$$x0
000292073 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x1
000292073 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000292073 9200_ $$0I:(DE-He78)Z999-20160331$$kZ999$$lErimitus im DKFZ$$x0
000292073 980__ $$ajournal
000292073 980__ $$aVDB
000292073 980__ $$aI:(DE-He78)Z999-20160331
000292073 980__ $$aI:(DE-He78)B062-20160331
000292073 980__ $$aI:(DE-He78)HD01-20160331
000292073 980__ $$aUNRESTRICTED